Curaleaf Defends Premium Bid for Aurora Amid ASC Ruling

  • Curaleaf's CEO Boris Jordan criticized Aurora's share issuance under an ATM program, calling it dilutive and inconsistent with Curaleaf's 86% premium offer.
  • Aurora stopped using its ATM program on August 18, 2026, after Curaleaf raised concerns.
  • Curaleaf's enhanced offer implies a price of approximately US$5.00 per share, an 86% premium over Aurora's unaffected volume weighted average share price of US$2.75.
  • Curaleaf claims Aurora is excluding it from customary diligence while engaging with other parties.
  • A combined entity would operate across 17 countries with US$1.5 billion in LTM revenue and US$350 million in LTM Adjusted EBITDA.

Curaleaf's defense of its premium bid for Aurora highlights ongoing tensions in the cannabis industry around shareholder value and governance. The strategic combination would create a global leader with significant revenue and EBITDA, but regulatory and governance hurdles remain. The outcome will test the balance between shareholder activism and board discretion in the sector.

Regulatory Scrutiny
How the Alberta Securities Commission's ruling will impact Aurora's share issuance practices and Curaleaf's bid.
Shareholder Dynamics
Whether Aurora shareholders will support Curaleaf's premium offer amid governance concerns.
Strategic Integration
The pace at which Curaleaf and Aurora can realize expected annual cost synergies of at least US$40 million.